File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Conference Paper: Cardiovascular safety of Janus kinase inhibitors in patients with rheumatoid arthritis: a meta-analysis

TitleCardiovascular safety of Janus kinase inhibitors in patients with rheumatoid arthritis: a meta-analysis
Authors
Issue Date2020
PublisherHong Kong Academy of Medicine Press. The Journal's web site is located at http://www.hkmj.org/
Citation
The 25th Annual Medical Research Conference, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, 18 January 2020. In Hong Kong Medical Journal, 2020, v. 26 n. 1, Suppl. 1, p. 32, abstract no. 52 How to Cite?
AbstractIntroduction: Janus kinase (JAK) inhibitors are a new class of medication approved for treating rheumatoid arthritis. As JAKs are involved in lipid metabolism, we investigated the cardiovascular safety of JAK inhibitors. Methods: Literature search was conducted using Medline, ISI Web of Science, Scopus, Embase and clinicaltrials.gov. Randomised controlled trials reporting major cardiovascular events or hypertension were included. Results were analysed using RevMan 5.3.5. Odds ratio (OR), mean difference, and 95% confidence interval (CI) were estimated using random-effects model. Results: A total of 23 studies were included in this meta-analysis. Janus kinase inhibitors were not associated with major cardiovascular events (OR=0.94, 95% CI=0.57-1.57). Tofacitinib was not associated with hypertension (OR=1.53, 95% CI=0.96-2.43). However, JAK inhibitors were associated with an increase in high-density lipoprotein (OR=10.11, 95% CI=8.03-12.19 mg/dL) and low-density lipoprotein cholesterol (OR=7.99, 95% CI=7.14-8.85 mg/dL), respectively. Conclusion: Although JAK inhibitors were not associated with increased major cardiovascular events, they were associated increased low-density lipoprotein and high-density lipoprotein. Tofacitinib was not associated with hypertension. Physicians should monitor the lipids of patients taking JAK inhibitors.
Persistent Identifierhttp://hdl.handle.net/10722/281730
ISSN
2019 Impact Factor: 1.679
2015 SCImago Journal Rankings: 0.279

 

DC FieldValueLanguage
dc.contributor.authorTsoi, MF-
dc.contributor.authorFei, Y-
dc.contributor.authorOr, CYB-
dc.contributor.authorCheung, TT-
dc.contributor.authorCheung, BMY-
dc.date.accessioned2020-03-22T04:18:51Z-
dc.date.available2020-03-22T04:18:51Z-
dc.date.issued2020-
dc.identifier.citationThe 25th Annual Medical Research Conference, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, 18 January 2020. In Hong Kong Medical Journal, 2020, v. 26 n. 1, Suppl. 1, p. 32, abstract no. 52-
dc.identifier.issn1024-2708-
dc.identifier.urihttp://hdl.handle.net/10722/281730-
dc.description.abstractIntroduction: Janus kinase (JAK) inhibitors are a new class of medication approved for treating rheumatoid arthritis. As JAKs are involved in lipid metabolism, we investigated the cardiovascular safety of JAK inhibitors. Methods: Literature search was conducted using Medline, ISI Web of Science, Scopus, Embase and clinicaltrials.gov. Randomised controlled trials reporting major cardiovascular events or hypertension were included. Results were analysed using RevMan 5.3.5. Odds ratio (OR), mean difference, and 95% confidence interval (CI) were estimated using random-effects model. Results: A total of 23 studies were included in this meta-analysis. Janus kinase inhibitors were not associated with major cardiovascular events (OR=0.94, 95% CI=0.57-1.57). Tofacitinib was not associated with hypertension (OR=1.53, 95% CI=0.96-2.43). However, JAK inhibitors were associated with an increase in high-density lipoprotein (OR=10.11, 95% CI=8.03-12.19 mg/dL) and low-density lipoprotein cholesterol (OR=7.99, 95% CI=7.14-8.85 mg/dL), respectively. Conclusion: Although JAK inhibitors were not associated with increased major cardiovascular events, they were associated increased low-density lipoprotein and high-density lipoprotein. Tofacitinib was not associated with hypertension. Physicians should monitor the lipids of patients taking JAK inhibitors.-
dc.languageeng-
dc.publisherHong Kong Academy of Medicine Press. The Journal's web site is located at http://www.hkmj.org/-
dc.relation.ispartofHong Kong Medical Journal-
dc.relation.ispartof25th Medical Research Conference-
dc.rightsHong Kong Medical Journal. Copyright © Hong Kong Academy of Medicine Press.-
dc.titleCardiovascular safety of Janus kinase inhibitors in patients with rheumatoid arthritis: a meta-analysis-
dc.typeConference_Paper-
dc.identifier.emailTsoi, MF: smftsoi@hku.hk-
dc.identifier.emailCheung, TT: tcheungt@hku.hk-
dc.identifier.emailCheung, BMY: mycheung@hkucc.hku.hk-
dc.identifier.authorityCheung, TT=rp01682-
dc.identifier.authorityCheung, BMY=rp01321-
dc.identifier.hkuros309418-
dc.identifier.volume26-
dc.identifier.issue1, Suppl. 1-
dc.identifier.spage32, abstract no. 52-
dc.identifier.epage32, abstract no. 52-
dc.publisher.placeHong Kong-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats